Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul 3;95(1):56-61.
doi: 10.1038/sj.bjc.6603210. Epub 2006 Jun 13.

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

H C Kitchener  1 , M Almonte, P Wheeler, M Desai, C Gilham, A Bailey, A Sargent, J Peto; ARTISTIC Trial Study Group
Affiliations

HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial

H C Kitchener et al. Br J Cancer. .

Abstract

To evaluate the effectiveness of human papillomavirus (HPV) testing in primary cervical screening. This was a cross-sectional study from the recruitment phase of a prospective randomised trial. Women were screened for HPV in addition to routine cervical cytology testing. Greater Manchester, attendees at routine NHS Cervical Screening Programme. In all, 24 510 women aged 20-64 screened with liquid-based cytology (LBC) and HPV testing at entry. HPV testing in primary cervical screening. Type-specific HPV prevalence rates are presented in relation to age as well as cytological and histological findings at entry. In all, 24 510 women had adequate cytology and HPV results. Cytology results at entry were: 87% normal, 11% borderline or mild, 1.1% moderate and 0.6% severe dyskaryosis or worse. Prevalence of HPV decreased sharply with age, from 40% at age 20-24 to 12% at 35-39 and 7% or less above age 50. It increased with cytological grade, from 10% of normal cytology and 31% of borderline to 70% mild, 86% moderate, and 96% of severe dyskaryosis or worse. HPV 16 or HPV 18 accounted for 64% of infections in women with severe or worse cytology, and one or both were found in 61% of women with severe dyskaryosis but in only 2.2% of those with normal cytology. The majority of young women in Greater Manchester have been infected with a high-risk HPV by the age of 30. HPV testing is practicable as a primary routine screening test, but in women aged under 30 years, this would lead to a substantial increase in retesting and referral rates. HPV 16 and HPV 18 are more predictive of underlying disease, but other HPV types account for 30% of high-grade disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ARTISTIC Trial protocol for the management of women with normal and abnormal cytology and HPV-positive and -negative tests, in the revealed arm.
Figure 2
Figure 2
Prevalence of high-risk HPV (HR HPV) by Hybrid Capture 2 (HC2) according to age quinquennia.
Figure 3
Figure 3
Prevalence of high-risk HPV (HR HPV) by Hybrid Capture 2 (HC2) by cytology grade within different age bands.
See this image and copyright information in PMC

References

    1. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366: 991–998 - PubMed
    1. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362: 1871–1876 - PubMed
    1. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247–1255 - PubMed
    1. IARC (1995) Monographs on the Evaluation of Carcinogenic Risks to Humans No. 64. Human Papillomaviruses. IARC: Lyon - PMC - PubMed
    1. IARC (2004) Cervix Cancer Screening/IARC Working Group on the Evaluation of Cancer – Preventive Strategies. IARC: Lyon. IARC Handbook of Cancer Prevention